SUPPLEMENTARY MATERIALS

Table S1 An overview of described study characteristics

Study/Country	Design	Study Participants	Dose/Route/Duration
AI444-005/ USA	Open-label, non-randomized, single-sequence study	Healthy (*N* = 14)	DCV 10 mg capsule/PO/single dose on Days 1 and 9; ketoconazole 400 mg tablet/PO/QD on Days 5–13.
AI444-008/ USA	Open-label, non-randomized, single-sequence study	Healthy (*N* = 18)	DCV 60 mg/PO/QD on Days 2–6; midazolam 5 mg/PO/QD on Days 1 and 6.
AI444-009/ USA	Open-label, randomized, 5-period, 5-treatment, crossover study	Healthy (*N* = 18)	Included: DCV 60 mg (6 × dry granulated 10 mg formulation) with (2-hours post-dose) or without famotidine 40 mg administered under fasted conditions.
AI444-012/ Korea	Open-label, single sequence, 1-way interaction study	Healthy (*N* = 14)	DCV 60 mg/PO/QD on Days 1 and 10; rifampin 600 mg/PO/QD on Days 3–11.
AI444-020/ USA and Canada	Open-label, 3-cycle, single-sequence study	Healthy WOCBP (*N* = 20)	DCV 60 mg/PO/QD on Days 68–77; Ortho Tri-Cyclen®/PO/QD on Days 1–77.
AI444-024/ USA	Open-label, randomized study	Healthy (*N* = 24; 12 per arm)	DCV 20 mg (Arm 1) or 60 mg (Arm 2)/PO/QD on Days 1 and 8; omeprazole 40 mg/PO/QD on Days 3–9.
AI444-027/ USA	Open-label, 2-treatment, single-sequence, multiple-dose, one-way interaction study	Healthy (*N* = 17)	Digoxin 0.125 mg/PO/QD on Days 1–20; DCV 60 mg/PO/QD on Days 11–20.
AI444-032/ USA	Open-label, two-treatment, single-sequence crossover, one-way interaction study	Healthy (*N* = 14)	DCV 60 mg (2 × 30 mg tablets)/PO/QD on Days 1–14; atazanavir/ritonavir 300/100 mg/PO/QD on Days 5–14.
AI444-033/ USA	Open-label, 3-treatment, randomized, multiple-dose, 3-way crossover, 2-way interaction study	Healthy (*N* = 21)	Treatment A: DCV 60 mg/PO/QD; Treatment B: tenofovir 300 mg/PO/QD; Treatment C: DCV 60 mg + tenofovir 300 mg/PO/QD. Each treatment was administered after a light breakfast for 7 days.
AI444-034/ USA	Open-label, three-treatment, single- sequence, multiple-dose, one-way interaction study	Healthy (*N* = 17)	Treatment A: DCV 60 mg /PO/QD on Days 1–4 Treatment B: Efavirenz 600 mg /PO/QD (administered in the evening) + DCV 60 mg /PO/QD administered in the morning on Days 5–13 Treatment C: Efavirenz 600 mg /PO/QD (administered in the evening) + DCV 120 mg /PO/QD administered in the morning on Days 14–18

AI444-043/ Multinational	Open-label, phase 3 efficacy and safety study	HIV/HCV co-infected patients on stable DRV/r (*n* = 11) or LPV/r (*n* = 6)	Patients receiving stable DRV/r (600/100 mg BID) or LPV/r (400/100 mg BID) received DCV 30 mg QD (+pegIFN/RBV).
AI444-054/ USA	Open-label, 3-treatment, single-sequence, 1-way interaction study	Healthy subjects (*N* = 22)	Rosuvastatin 10 mg/PO/QD on Days 1 and 10–13; DCV 60 mg/PO/QD on Days 10–13.
AI444-064/ USA	Open-label, 2-part, 1-way study	Healthy subjects (*N* = 14)	Stable-dose methadone or buprenorphine/naloxone on Days 1–9; DCV 60 mg/PO/QD on Days 2–9.
AI444-065/ USA	Open-label, single-sequence study	Healthy subjects (*N* = 28)	Group 1: cyclosporine 400 mg/PO/QD on Days 1 and 9; DCV 60 mg/PO/QD on Days 4–11. Group 2: tacrolimus 5 mg/PO/QD on Days 1 and 13; DCV 60 mg/PO/QD on Days 8–19.
AI444-067/ Japan	Open-label, uncontrolled study	Healthy subjects (*N* = 30)	Period 1: DCV 60 mg/PO/QD for 7 days; Period 2: telaprevir 500 mg/PO TID or 750 mg/PO/BID on Days 1–12; DCV 20 mg/PO/QD on Days 6–12.
AI444-084/ USA	Open-label, single-sequence, 2-way drug-drug interaction study	Healthy subjects (*N* = 15)	DCV 60 mg/PO/QD on Days 1–5 and 17–23; escitalopram 10 mg/PO/QD on Days 10–23.
AI444-093/ USA	Open-label, non-randomized, one-way drug-interaction study	Healthy subjects (*N* = 14)	DCV 60 mg/PO/QD on Days 1–4, and 30 mg/PO/QD on Days 5–14. Darunavir/r (800/100 mg/PO/QD) or lopinavir/r (400/100 mg/PO/BID) on Days 5–14.
AI447-009/ USA	Open-label, randomized, 2-sequence, multiple-dose drug-drug interaction study	Healthy subjects (*N* = 28)	Included: DCV 60 mg/PO/QD for 7 days followed by DCV 30 mg/PO/QD + ASV 200 mg/PO/BID .
AI447-011/ USA	Randomized, open-label, phase 2a efficacy and safety study	HCV GT1 patients (prior pegIFN non-responders; *N* = 22)	Included: DCV 60 mg/PO/QD + ASV 600 mg/PO/BID + pegIFN/RBV, and DCV 60 mg/PO/QD + ASV 200 mg/PO/BID + pegIFN/RBV.
AI447-040/ USA	Open label, single-sequence, drug-drug interaction study with digoxin	Healthy subjects (*N* = 16)	Digoxin 0.25 mg/PO/QD on Days 1 and 16; DCV 60 mg/PO/QD and ASV 100 mg PO/BID on Days 6–20.

ANRS HC30 QUADRIH/ France	Phase 2, open-label, single-arm study with a PK sub-study	HCV-HIV co-infected (focusing on patients on raltegravir, emtricitabine, and tenofovir; *N* = 18/20)	PK substudy: PegIFN/RBV lead-in period for 4 weeks followed by: DCV 60 mg/PO/QD + ASV 100 mg/PO/BID + pegIFN/RBV for 24 weeks
HCP1005/ USA	Open-label, 2-panel, randomized, 2-way safety and PK crossover study	Healthy subjects (*N* = 44)	DCV 60 mg/PO/QD and simeprevir 150 mg PO/QD, each administered alone and in combination for 7 days.
NCT02082808/ USA	Single-center, open-label, 3-period crossover study	Healthy subjects (*N* = 12)	Period 1: DCV 60 mg/PO/QD or dolutegravir 50 mg/PO/QD for 5 days; Period 2: Dolutegravir 50 mg/PO/QD or DCV 60 mg/PO/QD for 5 days; Period 3: DCV 60 mg/PO/QD + dolutegravir 50 mg/PO/QD for 5 days.

ASV asunaprevir, *BID* twice daily, *DCV* daclatasvir, *DRV* darunavir, *GT* genotype; *HCV* hepatitis C virus, *HIV* human immunodeficiency virus, *LPV* lopinavir, *pegINF* pegylated interferon, *PK* pharmacokinetic, *PO* by mouth, *QD* once daily, *RBV* ribavirin, *TID* three times daily, *WOCBP, women of child-bearing potential.*